Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Dehm

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Nature Communications|December 11, 2024
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patientsTodd P Knutson, Bin Luo, Anna Kobilka, et al.
Cancer Research|May 6, 2017
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate CancerSteve Paltoglou, Rajdeep Das, Scott L Townley, et al.
Oncotarget|July 25, 2025
Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancerAiden Deacon, Ava Gustafson, Allison Makovec, et al.
Molecular Cancer Research : MCR|September 22, 2022
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone TreatmentHugues Sicotte, Krishna R Kalari, Sisi Qin, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate CancerLisanne Mout, Thaidy Moreno-Rodriguez, Giacomo Grillo, et al.
NAR Cancer|August 28, 2023
Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancerAndrej Zivanovic, Jeffrey T Miller, Sarah A Munro, et al.
Molecular Cancer Therapeutics|August 5, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin InteractionsKush Dalal, Meixia Che, Nanette S Que, et al.
Communications Biology|April 14, 2023
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystemsHannah E Bergom, Ashraf Shabaneh, Abderrahman Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte IsolationJamie M Sperger, Lindsay N Strotman, Allison Welsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trialJosé C Valentín López, Chenxi Yu, Todd P Knutson, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Nature Communications|December 11, 2024
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patientsTodd P Knutson, Bin Luo, Anna Kobilka, et al.
Cancer Research|May 6, 2017
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate CancerSteve Paltoglou, Rajdeep Das, Scott L Townley, et al.
Oncotarget|July 25, 2025
Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancerAiden Deacon, Ava Gustafson, Allison Makovec, et al.
Molecular Cancer Research : MCR|September 22, 2022
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone TreatmentHugues Sicotte, Krishna R Kalari, Sisi Qin, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate CancerLisanne Mout, Thaidy Moreno-Rodriguez, Giacomo Grillo, et al.
NAR Cancer|August 28, 2023
Co-evolution of <i>AR</i> gene copy number and structural complexity in endocrine therapy resistant prostate cancerAndrej Zivanovic, Jeffrey T Miller, Sarah A Munro, et al.
Molecular Cancer Therapeutics|August 5, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin InteractionsKush Dalal, Meixia Che, Nanette S Que, et al.
Communications Biology|April 14, 2023
ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystemsHannah E Bergom, Ashraf Shabaneh, Abderrahman Day, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte IsolationJamie M Sperger, Lindsay N Strotman, Allison Welsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Evolution of AR and non-AR alterations in circulating tumor DNA of metastatic prostate cancer patients treated in the phase 3 Alliance A031201 trialJosé C Valentín López, Chenxi Yu, Todd P Knutson, et al.
Pageof 13